卵巢上皮性癌组织中Gab1与PDL1蛋白表达与临床病理特征及预后的相关性
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

重庆市科技局科研课题


The correlation analysis of the expression of Gab1 and PDL1 in epithelial ovarian carcinoma with clinicopathological features and prognosis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    【摘要】 目的 探讨卵巢上皮性癌组织中Gab1与程序性死亡配体1(PDL1)的表达情况,并分析Gab1、PDL1蛋白与卵巢上皮性癌患者临床病理特征及预后的相关性。方法 选取我院2008年5月~2014年5月收治的86例卵巢上皮性癌患者作为研究对象,采用回顾性分析法分析其临床及随访资料,收集86份癌组织标本(观察组)及86份癌旁正常组织标本(对照组),所有组织标本均行Gab1与PDL1蛋白检测,并根据其资料及检测结果记录所有患者年龄、体质量指数等一般临床资料及肿瘤情况、Gab1与PDL1蛋白水平及预后等。结果 观察组中Gab1及 PDL1蛋白的表达水平均显著高于对照组(P<0.05);随着卵巢上皮性癌患者临床分期更高、分化程度越低及出现淋巴结转移时其Gab1及 PDL1蛋白的阳性表达率也显著增高(P<0.05);Gab1阴性和阳性患者其3年总生存率分别为7273%和4286%,而 PDL1阴性和阳性患者其3年总生存率分别为7368%和4583%(P<0.05);经非条件单因素Cox 比例风险回归模型显示不同临床分期、分化程度、是否出现淋巴结转移以及Gab1和 PDL1不同表达的卵巢上皮性癌患者间其预后生存时间均存在差异(P<0.05);经多因素Cox 比例风险回归模型分析显示临床分期Ⅲ~Ⅳ期、低分化、出现淋巴结转移以及Gab1和 PDL1阳性均为影响卵巢上皮性癌患者预后的独立危险因素(P<0.05)。结论 Gab1和 PDL1蛋白在卵巢上皮性癌组织中均高表达,随着病情加重其阳性表达率更高,且其阳性表达联合临床分期Ⅲ~Ⅳ期、低分化和出现淋巴结转移均为影响卵巢上皮性癌患者预后生存的独立危险因素,故可将其作为临床上评估卵巢上皮性癌患者病情进展和预后的有效指标。

    Abstract:

    【Abstract】 Objective To investigate and analyze the expression of Gab1 and programmed death ligand1 (PDL1) in epithelial ovarian cancer tissues, and explore the correlation between Gab1, PDL1 protein and clinicopathological characteristics and prognosis in patients with epithelial ovarian cancer. Methods 86 epithelial ovarian cancer patients in our hospital from May 2008 to May 2014 were used as the objects in the study. The clinical value and followup data of all patients were analyzed by a retrospective analysis. Collecting 85 cancer tissues (observation group) and 86 adjacent normal tissues (the control group) from 86 epithelial ovarian cancer patients and used as the research objects according to the data. The protein level of Gab1 and PDL1 protein in all tissues were measured, and recording the patients age, body mass index and other clinical data and tumor, Gab1 and PDL1 protein levels and prognosis according to the data and test results. Results The expression levels of Gab1 and PDL1 in the epithelial ovarian carcinoma tissues of epithelial ovarian cancer patients were significantly higher than those in adjacent normal tissues (P<0.05). The positive expression of PDL1 Gab1 were increased significantly following with higher clinical stage lower the degree of differentiation and lymph node metastasis of epithelial ovarian cancer patients (P<0.05). The 3 year survival rates of patients with Gab1 positive and negative expressions were 7273% and 4286%, while the 3 year survival rates of patients with PDL1 positive and negative expressions were 7368% and 4583% (P<0.05). The results of single factor non conditional Cox regression model shows that there were differences in epithelial ovarian cancer patients with different clinical stages, differentiation, or lymph node metastasis and Gab1 and PDL1 expression between the prognosis of survival time (P<0.05). The results of multivariate Co X proportional hazards regression analysis indicated that clinical stage III, IV, poorly differentiated, lymph node metastasis and positive expressions of Gab1 and PDL1 were independent risk factors for the prognosis of epithelial ovarian cancer patients (P<0.05). Conclusion The expressions of Gab1 and PDL1 protein was increased in epithelial ovarian cancer, and increased with the aggravation. The positive expression of Gab1 and PDL1 combine with clinical stage III ~ IV, low differentiation and lymph node metastasis were independent prognostic risk factors in epithelial ovarian cancer patients. It can be used as the clinical evaluation index of progression and prognosis of epithelial ovarian cancer patients.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-09-10
您是第位访问者
版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司